Sharpen the Founder.
Elevate the Opportunity.
BLPN Money Ball is a capital readiness and investor relations program for early stage BLPN Operators who are serious about winning. From pitch development through active fundraising, it prepares founders to compete at the highest level in Life Sciences.
Inspired by the disciplined mindset that once reshaped professional sports, Money Ball embraces a philosophy of uncovering hidden value and building competitive advantage. At BLPN, we apply that contrarian lens to Life Sciences startups, identifying emerging assets, founders, and science, then deploying resources, connections, and strategy with precision and speed.
Money Ball activates BLPN’s network of experienced Life Sciences dealmakers and partners to deliver direct investor feedback, focused mentorship, and market insight. The goal is simple: unlock undervalued potential and increase both performance and perceived value. The result is a disciplined, high performance model that converts early potential into breakout outcomes in the competitive arena of Life Sciences innovation.
Players: Refine your positioning. Strengthen your pitch. Increase investor exposures and create more meaningful at bats.
Coaches: Share your experience and network to help shape the next generation of Life Sciences leaders and build investable companies.
Vetted | BLPN Community
Coached | BLPN Dealmakers
Funded | BLPN Investors
Podcasts Featuring Money Ball
The Healthy Enterprise Podcast: James Lovgren, Aspiro Therapeutics
In this conversation, James Lovgren shares his insights on the funding process for biotech startups, emphasizing the importance of team expertise, the art of pitching, and the need to balance scientific detail with storytelling.
The Healthy Enterprise Podcast: Robert Boyce, Plakous Therapeutics
In this episode, Rob Boyce, CEO of Plakous Therapeutics, discusses the company's mission to develop regenerative medicine solutions for necrotizing enterocolitis (NEC), a devastating disease affecting premature infants.
The Healthy Enterprise Podcast: Doug Cohen, IR Medtek
In this episode of The Healthy Enterprise, host Heath Fletcher interviews Doug Cohen, the Co-Founder and CEO of IR Medtek, about his journey in developing a groundbreaking technology for cancer detection.
The Healthy Enterprise Podcast: Chandi Bandara, Precision Quantomics
In this episode of The Healthy Enterprise, host Heath Fletcher speaks with Chandi Bandara, CEO of Precision Quantomics, about the challenges and innovations in drug development. They discuss the inefficiencies in the pharmaceutical industry, the importance of effective pitching to investors, and the insights gained from the Money Ball program.
Selling Science Podcast: Linda Templeman, Persista Bio LSX
Recorded live at LSX, Linda Templeman of Persista Bio sits down with Selling Science Podcast to discuss the evolving biomarker landscape and how data-driven diagnostics are reshaping oncology investment and partnering opportunities.
“One of the greatest strengths of this program was the people. The coaches never held back in their input, and that honesty and candor were a major plus. Beyond that, so many other members also stepped in to support and guide me throughout—reminding me that this truly is a community built on collective success.”
— Chandi Bandara, Money Ball BIO 2025 Player, CEO, Precision Quantomics
“Very valuable and helpful. It provided some real world feedback and some great connections for us moving forward. Coaches are awesome and do a nice job of guidance and discussion as we refined our message.”
— Doug Cohen, Money Ball BIO 2025 Player, CEO, IR Medtek
“The respect, collaboration and support that the BLPN team engenders - even when many balls are in the air and adjustments are being made - that's what makes this an incredible experience and worth the time and effort. So a big, heart-felt THANK YOU!”
— Michael Hill, Money Ball BIO 2025 Head Coach, Co-Founder of Science Innovations, LLC
“From my perspective as Head Coach, the real value of the Money Ball program is that it takes brilliant founders and gives them the structure, discipline, and confidence to step into the investor arena. Founders often start with powerful science but without a clear commercial identity or investor-ready story. Money Ball closes that gap. It equips CEOs with the tools—licensing strategy, valuation benchmarks, pitch discipline, and clear milestones—that transform an early-stage idea into a fundable company. . . .”
— Stella Vnook, Head Coach for BIO 2025, Founder of Agile Consulting Group